May 234BIO Capital Portfolio Company Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease
May 16, 20234BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing
May 9, 20234BIO Capital Participates in $130M Funding of New Gene and Cell Manufacturing Specialist Ascend
Dec 1, 2022SparingVision’s lead asset SPVN06 clears IND application in the US for retinitis pigmentosa